AVEO Oncology is passionate in our pursuit of improving the lives of patients with cancer.
Find out More
Neuropilin 1 may be Prognostic and Identify a Subgroup of Patients with Metastatic Colorectal Cancer who Benefit from from Tivozanib + mFOLFOX6 Compared to Bevacizumab + mFOLFOX6
July 3, 2015
Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody
April 20, 2015
No Recent Events
AVEO Oncology Announces Additional Biomarker Analyses from BATON-CRC Tivozanib Study to be Presented at the ESMO 17th World Congress on Gastrointestinal Cancer
June 30, 2015
AVEO Announces FDA Update for Tivozanib in Colorectal Cancer
June 11, 2015
AVEO Announces Receipt of European Regulatory Guidance Regarding Potential Marketing Authorization Application for Tivozanib
June 3, 2015
© 2015 AVEO Pharmaceuticals, Inc. All rights reserved.